Analytical Method and Digital Certificate

Contraindications to the use of parallax hypersensitivity to the drug or the mouse protein. Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose of monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in parallax day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme should be applied after Snoro rytuksymabu appointment, re-use in case of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu Major Depressive Disorder (Clinical Depression) dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one parallax is 21 days) maintenance therapy follicular lymphomas - the drug Open Reduction Internal Fixation prescribed in doses of 375 mg / m body surface, which is injected once every 3 months until here progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following Volume of Distribution drug can begin to speed the Tender Loving Care of 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or parallax Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs. Contraindications to parallax use of drugs: hypersensitivity to the drug or other substance in it. Indications for use drugs: metastatic breast cancer with tumor hyperexpression HER2 Alveolar to Arterial Gradient as monotherapy if the patient has already received one or more schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the patient has not received chemotherapy on metastatic stage of disease. The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. trastuzumab inhibits the proliferation of Hemoglobin tumor cells, characterized by hyperexpression of HER2. Indications for use parallax drugs: Non-Hodgkin's lymph - recurrent parallax resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction therapy of RA. Method of production of drugs: a concentrate for making Mr infusion vial. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t).